tert-butyl (trans-4-piperidin-1-ylcyclohexyl)carbamate | 937072-68-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl (trans-4-piperidin-1-ylcyclohexyl)carbamate
• CAS: 937072-68-9
• 化学式: C₁₆H₃₀N₂O₂
• 分子量: 282.426
• InChiKey: LBFXRWKOOTUMJS-HDJSIYSDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.31
• 重原子数：
  20.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  41.57
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (trans-4-piperidin-1-ylcyclohexyl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 (1R,4R)-4-(piperidin-1-yl)cyclohexanamine hydrochloride
  参考文献：
  名称：

  [EN] PYRAZOLOTRIAZINE DERIVATIVES USEFUL AS CDK9 INHIBITORS
  [FR] DÉRIVÉS DE PYRAZOLOTRIAZINE UTILES EN TANT QU'INHIBITEURS DE CDK9

  摘要：

  The present invention relates to novel compounds of formula (I). These compounds are inhibitors of CDK2 and/or CDK9 and are useful in the treatment of a variety of diseases including hyperproliferative diseases, virally induced infectious diseases, and cardiovascular diseases.

  公开号：

  WO2023094310A1
• 作为产物：
  描述：

  1,5-二碘戊烷 、 TRANS-N-BOC-1,4-CYCLOHEXANEDIAMINE 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 16.0h， 生成 tert-butyl (trans-4-piperidin-1-ylcyclohexyl)carbamate
  参考文献：
  名称：

  [EN] PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF
  [FR] DÉRIVÉ DE PYRAZOLE PYRIMIDINE ET UTILISATIONS DE CELUI-CI

  摘要：

  本发明提供了抑制酪蛋白激酶I（CKI）和/或白细胞介素-1受体相关激酶1（IRAK1）的吡唑嘧啶衍生物，以及它们的制备方法、包含它们的组合物和在治疗恶性疾病和紊乱的方法中的用途，以及治疗炎症性疾病和紊乱的方法。

  公开号：

  WO2017021969A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'UNE PROLIFÉRATION CELLULAIRE ANORMALE
  申请人：G1 THERAPEUTICS INC

  公开号：WO2019136244A1

  公开（公告）日：2019-07-11

  This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

  这项发明涉及杂环基化合物领域，用于治疗涉及异常细胞增殖的疾病，包括但不限于肿瘤和癌症。
• [EN] TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES NÉOPLASIQUES RÉSISTANT AUX INHIBITEURS DE CDK4/6
  申请人：G1 THERAPEUTICS INC

  公开号：WO2020206035A1

  公开（公告）日：2020-10-08

  This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

  这项发明涉及治疗涉及异常细胞增殖并对选择性CDK4/6抑制剂产生抗性的疾病的方法。
• Chemokine receptor antagonists and use thereof
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US08168783B2

  公开（公告）日：2012-05-01

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  化合物的一般式表示为（I）的化合物：其盐，其溶剂化合物或其前药，其中所有符号如规范所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如炎症和免疫性疾病（例如类风湿性关节炎，关节炎，系统性红斑狼疮，视网膜病变，黄斑变性，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），心理神经疾病，脑部疾病，心脏/血管疾病（例如动脉硬化，心肌梗塞，心绞痛，脑梗塞，慢性动脉闭塞性疾病等），代谢性疾病和癌症性疾病（例如癌症，癌症转移等），用作预防和/或治疗癌症性疾病或感染的药物，或用作再生治疗剂。
• CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF
  申请人：Kokubo Masaya

  公开号：US20120207765A1

  公开（公告）日：2012-08-16

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  通式（I）所代表的化合物：其盐、溶剂化物或前药物，其中所有符号均如规范中所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、系统性红斑狼疮、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、心理神经疾病、脑部疾病、心脏/血管疾病（例如动脉硬化、心肌梗死、心绞痛、脑梗死、慢性动脉闭塞性疾病等）、代谢性疾病和癌症性疾病（例如癌症、癌症转移等），是用于癌症性疾病或感染的预防和/或治疗剂，或再生疗法的剂。
• Pyrazole pyrimidine derivative and uses thereof
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem LTD

  公开号：US10376511B2

  公开（公告）日：2019-08-13

  The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

  本发明提供了抑制酪蛋白激酶 I（CKI）和/或白细胞介素-1 受体相关激酶 1（IRAKI）的吡唑嘧啶衍生物及其制造方法、包含它们的组合物以及它们在治疗恶性疾病和紊乱以及治疗炎症性疾病和紊乱的方法中的用途。